Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Rani Therapeutics Holdings Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
RANI
Nasdaq
8731
https://www.ranitherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Rani Therapeutics Holdings Inc
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript
- Mar 21st, 2024 1:45 pm
RANI: 2023 Results
- Mar 21st, 2024 11:40 am
Q4 2023 Rani Therapeutics Holdings Inc Earnings Call
- Mar 21st, 2024 10:35 am
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
- Mar 20th, 2024 8:05 pm
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
- Mar 15th, 2024 8:05 pm
Individual investors own 40% of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shares but private companies control 47% of the company
- Mar 12th, 2024 10:06 am
RANI: INITIATION – Realizing Oral Administration of Biologics
- Feb 20th, 2024 9:29 am
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)
- Feb 5th, 2024 1:00 pm
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist
- Dec 14th, 2023 1:00 pm
What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock
- Dec 7th, 2023 5:00 pm
Jean-Luc Butel Buys Handful Of Shares In Rani Therapeutics Holdings
- Nov 24th, 2023 10:29 am
Pleasing Signs As A Number Of Insiders Buy Rani Therapeutics Holdings Stock
- Nov 24th, 2023 10:29 am
Rani Therapeutics Holdings Inc (RANI) Reports Q3 2023 Financial Results and Corporate Developments
- Nov 8th, 2023 10:53 pm
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update
- Nov 8th, 2023 9:05 pm
Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results
- Nov 1st, 2023 8:05 pm
The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study
- Oct 25th, 2023 12:00 pm
Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study
- Oct 19th, 2023 8:05 pm
Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research
- Oct 12th, 2023 8:05 pm
Private companies invested in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) copped the brunt of last week's US$18m market cap decline
- Oct 3rd, 2023 11:38 am
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
- Sep 18th, 2023 12:00 pm
Scroll